| 0.0001 0 (0%) | 07-14 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Evelo Biosciences, Inc. is a biotechnology firm dedicated to identifying and advancing oral biologic therapies for various inflammatory conditions and oncological diseases. Its pipeline includes EDP1815, a whole-microbe compound designed to address inflammatory ailments, currently undergoing Phase 2 clinical trials for conditions such as psoriasis and atopic dermatitis, and also being evaluated for the hyperinflammatory reaction associated with COVID-19. Additional developments include EDP1867, an inactivated oral biologic in Phase 1b for inflammatory diseases; EDP2939, an investigational oral biologic based on extracellular vesicles targeting inflammatory diseases; and EDP1908, a drug candidate focused on cancer. Established in 2014, Evelo Biosciences, Inc. operates from its headquarters in Cambridge, Massachusetts.
Mon, 13 Jul 2026
Price to earnings forward of Evelo Biosciences, Inc. – OTC:EVLO - TradingView
Wed, 22 Nov 2023
Flagship-backed microbiome biotech Evelo to shut down - BioPharma Dive
Wed, 01 Feb 2023
Evelo Biosciences Provides Clinical and Business Updates - citybiz
Thu, 11 Aug 2022
Evelo Biosciences Promotes Simba Gill To Chair of the Board of Directors - citybiz
Thu, 16 Jun 2022
Evelo Biosciences Inc. (EVLO) Share Price Today | Evelo Biosciences (EVLO) Live NSE/BSE - Value Research
Tue, 07 Jun 2022
Cytovia Therapeutics Appoints Luca Scavo as Chief Financial Officer and James Priour as Chief Product Officer - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
OTC
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|